EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.
- FDA approval of WiSE CRT System in April 2025
- Initiation of U.S. commercial implants and $1.6 million revenue
- CMS reimbursement pathways established with $63,300 contract price
- Commencement of post-approval and feasibility clinical studies
- A$79.5 million capital raise completed to fund commercialization
EBR Systems’ Transition to Commercialisation
In 2025, EBR Systems, a Silicon Valley-based medical device company, achieved a landmark milestone by securing FDA approval for its WiSE CRT System, the world’s only wireless leadless cardiac pacing device designed for heart failure patients. This approval, granted in April, enabled EBR to shift from a development-stage enterprise to an active commercial medical device company.
The company launched its U.S. commercial implants in June 2025, marking the start of revenue-generating procedures. By year-end, EBR had completed 30 commercial implants across pilot and Limited Market Release phases, resulting in $1.6 million (A$2.4 million) in revenue. This initial commercial traction reflects early clinical adoption and growing physician engagement with the WiSE technology.
Reimbursement and Market Access Foundations
Critical to EBR’s commercial strategy was the establishment of reimbursement pathways with the U.S. Centers for Medicare & Medicaid Services (CMS). In August 2025, CMS approved the New Technology Add-On Payment (NTAP) for inpatient Medicare procedures at the maximum rate, followed by Transitional Pass-Through (TPT) reimbursement for outpatient procedures in September. Both programs commenced on 1 October 2025 and are set for three years, enabling a contract price of US$63,300 for the WiSE CRT System. These reimbursement milestones underpin broader adoption by mitigating financial barriers for hospitals and healthcare providers.
EBR’s Limited Market Release targeted select high-volume U.S. centres to support controlled scaling, physician training, and workflow optimisation. The company reported accelerating implant volumes into early 2026, with 25 cases in the first two months and 46 physicians trained to implant the device.
Clinical Evidence and Innovation Pipeline
To support ongoing clinical validation, EBR commenced the WiSE-UP post-approval study in late 2025, enrolling patients to evaluate real-world outcomes over five years. Additionally, the Totally Leadless CRT (TLC-AU) feasibility study began in December 2025 in Australia, exploring a fully leadless cardiac resynchronisation therapy approach by co-implanting WiSE with a leadless pacemaker. Success in this study could significantly expand EBR’s addressable market beyond the current upgrade patient population.
EBR also strengthened its intellectual property portfolio with new U.S. and Japanese patents, extending protection to 2043. This robust IP position is a key competitive advantage in the evolving cardiac rhythm management landscape.
Financial Position and Outlook
Despite commercial progress, EBR reported a net loss of US$48.8 million for 2025, reflecting continued investments in sales, marketing, research and development, and manufacturing scale-up. The company completed a substantial A$79.5 million capital raise in Q2 2025, bolstering its cash position to US$54.2 million (A$81.1 million) at year-end, providing runway to support initial commercialisation efforts.
EBR’s management acknowledges substantial doubt about the company’s ability to continue as a going concern without additional capital. The company plans to expand its sales force and marketing activities in 2026, pursue regulatory approvals in Australia, the UK, and the European Union, and continue generating clinical evidence to support long-term growth.
Risks and Challenges Ahead
EBR faces typical early commercialisation risks including manufacturing scale-up challenges, market acceptance hurdles, regulatory compliance demands, and competitive pressures from established cardiac device companies. The company’s reliance on single-source suppliers and the need to maintain robust intellectual property protection add further complexity. Additionally, the timing and impact of the planned reverse stock split, approved by shareholders in March 2026 but not yet effective, remain to be seen.
Bottom Line?
EBR Systems’ FDA approval and initial commercial momentum set the stage for growth, but financial sustainability and market adoption remain critical hurdles in 2026.
Questions in the middle?
- How quickly will EBR expand its U.S. implant volumes and physician training?
- What are the prospects and timelines for regulatory approvals outside the U.S.?
- Will ongoing clinical studies validate broader indications and drive market expansion?